China Biologic Products to Present at CCG IR’s China Rising Conference and Oppenheimer’s China Dragon Call Conference in New York
TAIAN CITY,
Biologic Products, Inc. (OTC Bulletin Board: CBPO) (”China Biologic” or the
”Company”), one of the leading plasma-based pharmaceutical companies in
People’s Republic of China
management will present at the upcoming China Rising Conference hosted by CCG
Investor Relations in
Dragon Call Conference hosted by Oppenheimer & Co. Inc. on
The date, time and location of China Biologic’ presentation at the China
Rising Conference is as follows:
Date: Monday, May 18, 2009
Time: 10:30 a.m. to 11:00 a.m. Eastern Time
Presenter: Tristan Kuo, Chief Financial Officer of China
Biologic
Venue: The Yale Club
50 Vanderbilt Avenue
New York, NY 10017
Webcast: http://www.chinarisingconference.com/webcast.html
A replay of the webcast will be available for up to one year following the
presentation using the same link.
The China Rising Investment Conference hosted by CCG Investor Relations
will provide over 250 fund managers and investors access to senior management
of a wide range of Chinese growth companies in sectors including consumer
staples, agriculture, pharmaceuticals, infrastructure, information technology,
advanced materials, capital goods, and alternative energy. The conference will
include over 30 US-listed Chinese companies and a number of private companies.
Interested parties and investors may find more information for the
conference by visiting the website at http://www.chinarisingconference.com .
The date, time and location of China Biologic’s presentation at the
Oppenheimer 3rd Annual China Dragon Call Conference are as follows:
Date: Tuesday, May 19, 2009
Time: 10:15 p.m. to 10:45 p.m. Eastern Time
Presenter: Tristan Kuo, Chief Financial Officer of China Biologic
Venue: 300 Madison Avenue
New York City
The China Dragon Call Conference hosted by Oppenheimer & Co. Inc. will
provide intimate access to senior management of leading Chinese companies.
These discussions will give investors an ability to analyze secular trends, to
identify emerging opportunities and to gather insight into
outlook.
All conferences are for institutional clients of Oppenheimer & Co. Inc.
and are by invitation only. For more information, please contact Oppenheimer &
Co. Inc. institutional sales representative.
About China Biologic Products, Inc.
China Biologic Products, Inc. (the ”Company”), through its indirect
majority-owned subsidiary, Shandong Taibang Biological Products Co. Ltd., and
equity investments in Xi’an Huitian Blood Products Co., Ltd. and Chongqing
Dalin Biologic Technologies Co., Ltd. is currently the largest non-state-owned
plasma-based biopharmaceutical company approved by the Chinese government. The
Company is a fully integrated biologic products company with plasma collection,
production and manufacturing, research and development, and commercial
operations. The Company’s blood products are irreplaceable in the application
of medical emergencies, and prevention and treatment for various diseases. It
sells its plasma-based biopharmaceutical products to hospitals and other
healthcare facilities in
Safe Harbor Statement
This release may contain certain ”forward-looking statements” relating
to the business of China Biologic Products, Inc. and its subsidiary companies.
All statements, other than statements of historical fact included herein are
”forward-looking statements,” including statements regarding: the ability of
the Company to achieve its commercial objectives; the business strategy, plans
and objectives of the Company and its subsidiaries; and any other statements
of non-historical information. These forward-looking statements are often
identified by the use of forward-looking terminology such as “believes,”
”expects” or similar expressions, involve known and unknown risks and
uncertainties. Although the Company believes that the expectations reflected
in these forward-looking statements are reasonable, they do involve
assumptions, risks and uncertainties, and these expectations may prove to be
incorrect. Investors should not place undue reliance on these forward-looking
statements, which speak only as of the date of this press release. The
Company’s actual results could differ materially from those anticipated in
these forward-looking statements as a result of a variety of factors,
including those discussed in the Company’s periodic reports that are filed
with the Securities and Exchange Commission and available on its website
(http://www.sec.gov). All forward-looking statements attributable to the
Company or persons acting on its behalf are expressly qualified in their
entirety by these factors. Other than as required under the securities laws,
the Company does not assume a duty to update these forward-looking statements.
For more information, please contact:
Company Contact:
Mr. Y. Tristan Kuo
Chief Financial Officer
China Biologic Products, Inc.
Tel: +86-538-6202206
Email: IR@chinabiologic.com
Web: http://www.chinabiologic.com
Investor Relations Contact:
Mr. Crocker Coulson, President
CCG Investor Relations
Tel: +1-646-213-1915 (NY office) or
Mr. Gary Chin
Tel: +1-646-213-1909
Email: crocker.coulson@ccgir.com
Web: http://www.ccgirasia.com
SOURCE China Biologic Products, Inc.